Targeting Senescent Alveolar Type 2 Cells with a Gene-Editable FePt Dual-Atom Catalyst for Mitigating Idiopathic...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pulmonary Medicine

Background:

• Idiopathic pulmonary fibrosis (IPF) is a fatal, incurable lung disease with a high unmet medical need.
• Cellular senescence in alveolar type 2 (AT2) cells is a key driver of IPF.
• Current antifibrotic therapies have limitations, necessitating novel therapeutic strategies.

Purpose of the Study:

• To develop and evaluate an inhalable gene-editable nanoplatform for treating IPF.
• To target cellular senescence and reduce fibrosis in AT2 cells.
• To investigate the therapeutic potential of the nanoplatform in preclinical models.

Main Methods:

• Development of an inhalable nanoplatform (FePtR@HA) combining CRISPR-Cas9 gene editing and a FePt diatomic catalyst with a hyaluronic acid coating.
• Utilizing the FePt catalyst to clear reactive oxygen species (ROS) and reduce oxidative stress in AT2 cells.
• Employing CRISPR-Cas9 to knock down the pro-aging gene KAT7, thereby reducing senescence-associated secretory phenotype (SASP) factors.
• Evaluating the nanoplatform's efficacy in a lung-on-a-chip model and IPF mouse models.

Main Results:

• The FePtR@HA nanoplatform demonstrated efficient ROS clearance and antioxidant effects in AT2 cells.
• Gene editing of KAT7 successfully reduced SASP factors and reversed AT2 cell senescence.
• The nanoplatform reprogrammed the fibrotic microenvironment in a lung-on-a-chip model, inhibiting myofibroblast recruitment.
• FePtR@HA significantly alleviated lung fibrosis in IPF mouse models.

Conclusions:

• The inhalable FePtR@HA nanoplatform offers a dual-action therapeutic strategy for IPF by addressing cellular senescence and fibrosis.
• This approach shows significant promise for combating the progression of idiopathic pulmonary fibrosis.
• FePtR@HA represents a highly promising therapeutic intervention for age-related fibrotic lung diseases.